4.7 Article

The SLE-key test serological signature: new insights into the course of lupus

期刊

RHEUMATOLOGY
卷 57, 期 9, 页码 1632-1640

出版社

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/key149

关键词

autoantibodies; diagnosis; iCHIP; SLE-key; microarray; systemic lupus erythematosus; natural history; multivariate classifier

资金

  1. ImmunArray

向作者/读者索取更多资源

Objective. We previously described the multiplex autoantibody SLE-key Rule-Out test, which detects a signature of autoantibody reactivity that distinguishes healthy subjects from SLE patients with 94% sensitivity, 75% specificity and 93% negative predictive value; thus, an individual manifesting a positive Rule-Out test score is unlikely to have SLE (e.g. lupus is excluded). The objective of this current study was to evaluate the stability of the lupus-associated signature over time. Methods. We used banked serum samples from healthy subjects (n = 51) and lupus patients (n = 50 individual samples and n = 181 paired samples, for a total of n = 412 serum samples). The samples were drawn at different times after diagnosis to analyse the impact on the SLE-key Rule-Out test of time elapsed since diagnosis and any changes in disease activity (as reflected by the SLEDAI score). Results. The SLE signature remains stable for the first 10 years after diagnosis; in this time frame, < 10% of patients manifested a positive Rule-Out score and the SLE-key Rule-Out score was independent of the underlying disease activity as reflected by the SLEDAI score. After 510 years, similar to 30% of lupus subjects scored as SLE Ruled-Out; the proportion of patients manifesting this status was even greater in the subset of individuals with a SLEDAI score of 0. Conclusion. These findings raise the possibility that a significant number of SLE patients manifest a change in their serological signature over time, and that such a signature change may signify an evolution in the immunological features of their disease relevant to patient management.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity

Samar M. Hammad, Jasmyn R. Hardin, Dulaney A. Wilson, Waleed O. Twal, Paul J. Nietert, James C. Oates

PLOS ONE (2019)

Article Medicine, Research & Experimental

Peer approaches to self-management (PALS): comparing a peer mentoring approach for disease self-management in African American women with lupus with a social support control: study protocol for a randomized controlled trial

Edith M. Williams, Leonard Egede, Jim C. Oates, Clara L. Dismuke, Viswanathan Ramakrishnan, Trevor D. Faith, Hetlena Johnson, Jillian Rose

TRIALS (2019)

Article Genetics & Heredity

Differential DNA Methylation Landscape in Skin Fibroblasts from African Americans with Systemic Sclerosis

DeAnna Baker Frost, Willian da Silveira, E. Starr Hazard, Ilia Atanelishvili, Robert C. Wilson, Jonathan Flume, Kayleigh L. Day, James C. Oates, Galina S. Bogatkevich, Carol Feghali-Bostwick, Gary Hardiman, Paula S. Ramos

Summary: This study found widespread hypomethylation in dermal fibroblasts from African American patients with SSc, with enrichment of genes and pathways related to interferon signaling and mesenchymal differentiation, indicating potential new targets for further research.
Article Rheumatology

Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Ellen Ginzler, Luiz Sergio Guedes Barbosa, David D'Cruz, Richard Furie, Kathleen Maksimowicz-McKinnon, James Oates, Mittermayer Barreto Santiago, Amit Saxena, Saira Sheikh, Damon L. Bass, Susan W. Burriss, Jennifer A. Gilbride, James G. Groark, Michelle Miller, Amy Pierce, David A. Roth, Beulah Ji

Summary: The study aimed to assess the efficacy and safety of intravenous belimumab plus standard therapy in patients of self-identified Black race with systemic lupus erythematosus. While the primary endpoint was not achieved, numerical improvements favoring belimumab were observed, especially in patients with high disease activity or renal manifestations. The safety profile of belimumab was consistent with previous SLE trials.

ARTHRITIS & RHEUMATOLOGY (2022)

Article Rheumatology

Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis

Lindsay N. Helget, David J. Dillon, Bethany Wolf, Laura P. Parks, Sally E. Self, Evelyn T. Bruner, Evan E. Oates, Jim C. Oates

Summary: This study developed machine learning models using renal pathology results and clinical laboratory data to predict outcomes of lupus nephritis patients at approximately 1 year, providing a valuable tool for clinical decision-making.

LUPUS SCIENCE & MEDICINE (2021)

Article Rheumatology

A Distinct Plasma Microbiome But Not Gut Microbiome in Patients With Systemic Lupus Erythematosus Compared to Healthy Individuals

Warren A. James, Elizabeth Ogunrinde, Zhuang Wan, Diane L. Kamen, Jim Oates, Gary S. Gilkeson, Wei Jiang

Summary: This study analyzed the blood and stool samples from patients with systemic lupus erythematosus (SLE) and healthy controls (HCs) to investigate the microbial community composition. It was found that the plasma microbiome had distinct community and greater heterogeneity compared to the gut microbiome. The decreased plasma alpha diversity in patients with SLE suggests an altered plasma microbiome, which may play a role in the immune perturbations and pathogenesis of SLE.

JOURNAL OF RHEUMATOLOGY (2022)

Article Urology & Nephrology

Prediction models of treatment response in lupus nephritis

Isabelle Ayoub, Bethany J. Wolf, Linyu Geng, Huijuan Song, Aastha Khatiwada, Betty P. Tsao, Jim C. Oates, Brad H. Rovin

Summary: A machine learning approach combining traditional clinical data and novel urine biomarkers was used to develop prediction models for one-year treatment response in lupus nephritis. The models showed good predictive value, with the best performance seen in predicting eGFR response. The inclusion of both traditional clinical data and novel urine biomarkers, including cytokines, chemokines, and markers of kidney damage, was found to improve the prediction accuracy.

KIDNEY INTERNATIONAL (2022)

Article Biochemistry & Molecular Biology

Glycosphingolipid Levels in Urine Extracellular Vesicles Enhance Prediction of Therapeutic Response in Lupus Nephritis

Brian Troyer, Jessalyn Rodgers, Bethany J. Wolf, James C. Oates, Richard R. Drake, Tamara K. Nowling

Summary: The development of nephritis increases the risk of morbidity and mortality in systemic lupus erythematosus patients. Standard induction therapies are only effective for approximately 50% of SLE patients with nephritis, and there is a critical need to predict treatment response before starting therapy. Elevated urine glycosphingolipids (GSLs) may serve as a potential biomarker for predicting treatment response in lupus nephritis patients.

METABOLITES (2022)

Article Immunology

Staphylococcus aureus peptidoglycan (PGN) induces pathogenic autoantibody production via autoreactive B cell receptor clonal selection, implications in systemic lupus erythematosus

Wangbin Ning, Da Cheng, Philip H. Howe, Chuanxiu Bian, Diane L. Kamen, Zhenwu Luo, Xiaoyu Fu, Elizabeth Ogunrinde, Liuqing Yang, Xu Wang, Quan-Zhen Li, Jim Oates, Weiru Zhang, David White, Zhuang Wan, Gary S. Gilkeson, Wei Jiang

Summary: The interaction between the microbiome and the immune response plays a crucial role in the development of normal immunity and autoimmunity. This study found that peptidoglycan (PGN) from different bacteria can have different effects on the production of autoantibodies: PGN from Bacillus subtilis drives the production of natural nonpathogenic autoantibodies, while PGN from Staphylococcus aureus induces the production of pathogenic autoantibodies.

JOURNAL OF AUTOIMMUNITY (2022)

Letter Rheumatology

Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity

Cecile M. Yelnik, Xianhong Xie, Marta M. Guerra, Nathalie Costedoat-Chalumeau, Arezou Khosroshahi, Diane L. Kamen, Noa Schwartz, Patricia Katz, Margaret Minett, R. Toby Amoss, April Fu, Gaelle Guettrot-Imbert, Estibaliz Lazaro, Veronique Le Guern, Jim Oates, Maria Dall Era, Jinoos Yazdany, Anna Molto, Mimi Y. Kim, Jane E. Salmon

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Health Care Sciences & Services

The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus

Ashley A. White, Brittany L. Smalls, Aissatou Ba, Trevor D. Faith, Viswanathan Ramakrishnan, Hetlena Johnson, Jillian Rose, Clara L. Dismuke-Greer, Jim C. Oates, Leonard E. Egede, Edith M. Williams

Summary: The study found that travel burden can have an effect on lupus patients' anxiety and depression levels.

HEALTHCARE (2021)

Article Rheumatology

The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients

Ashley A. White, Aissatou Ba, Trevor Daniel Faith, Viswanathan Ramakrishnan, Clara L. Dismuke-Greer, Jim C. Oates, Edith Marie Williams

Summary: The study aimed to assess the benefits of the Care-coordination Approach to Learning Lupus Self-Management (CALLS) intervention compared to existing lupus care. Results suggest that the CALLS intervention may improve aspects of SLE disease self-management, but further research is needed for validation.

LUPUS SCIENCE & MEDICINE (2021)

Review Medicine, General & Internal

Association Between the Anti-Aging Gene Klotho and Selected Rheumatologic Autoimmune Diseases

Dayvia L. Russell, Jim C. Oates, Margaret Markiewicz

Summary: Klotho, traditionally known for its anti-aging properties, is now being explored for its potential role in the pathogenesis of autoimmune diseases such as rheumatoid arthritis, calling for further research and study.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2021)

Article Rheumatology

Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells

Dayvia A. Russell, Margaret Markiewicz, Jim C. Oates

LUPUS SCIENCE & MEDICINE (2020)

Article Rheumatology

L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells

Joy N. Jones Buie, Dorea Pleasant Jenkins, Robin Muise-Helmericks, Jim C. Oates

LUPUS SCIENCE & MEDICINE (2019)

暂无数据